

**Poster session „Tumor immunology” at the 05<sup>th</sup> of May 2017, 12.45 – 02.00 p.m.**  
**Venue: University Hospital (Halle-Kroellwitz), Ernst-Grube-Straße 40; 06120 Halle, Building 6, Lobby**

No.	Presenter	Location	Title
<b>Greta Guarda / Shlomo Elias</b>			
1	Scattolin, Gloria	Padua, I	Mitochondrial reactive oxygen species sensitize T-ALL cells to apoptosis by engaging the OMA1-OPA1 axis
2	Lennicke, Claudia	Halle, D	Redox reactive seleno compounds as anti-cancer therapeutics
3	Bekeschus, Sander	Greifswald, D	Pro-oxidant tumor therapy in murine melanoma and pancreatic cancer
4	Tognon, Martina	Padua, I	Study of metabolic heterogeneity of tumors at clonal level and its modulation by anti-angiogenic therapy
5	Cárdenas-Conejo Zugey, Elizabeth	Regensburg, D	Effects of 2-hydroxyglutarate on DC activation
6	Pane, Antonio	Heidelberg, D	Identification of microRNAs affecting recognition of melanoma cells by tumor antigen specific CD8 <sup>+</sup> T cells
7	Zhao, Fang	Essen, D	Altered T cell recognition of long-term BRAF inhibitor-treated melanoma cells
8	Wehner, Rebecca	Dresden, D	Phenotype of infiltrating human 6-sulfo LacNAc dendritic cells in renal and colon cancer
9	Wickenhauser, Claudia	Halle, D	Multi-spectral imaging – new diagnostic aspects in oral squamous cell carcinoma
10	Bukur, Jürgen	Halle, D	Nanostring analysis as a novel method for immune monitoring of checkpoint inhibitor therapies
11	Malle, Brahima Woldesonbet, Zelalem Yohannes, Meron	Addis Ababa, ETH	Triple negative breast cancer in Africa - a joint collaboration of the Universities Halle, Addis Ababa and Bamako
12	Heimes, Anne-Sophie	Mainz, D	Subtype-specific prognostic impact of different gene expression signatures in node-negative breast cancer
13	Huebner, Hanna	Erlangen, D	TILGen study – Identification of tumor specific mutations for cell based immunotherapy of breast cancer patients
14	Rühland, Svenja	Munich, D	Therapeutic potential of mesenchymal stem cells and cytotoxic T cells analyzed using tumor spheroids
15	Kegler, Alexandra	Dresden, D	Engineering human regulatory T cells with a novel modular chimeric antigen receptor technology
16	Mitwasi, Nicola	Dresden, D	Retargeting of T lymphocytes to GD2 expressing tumors using the novel switchable CAR platform technology “UniCAR”
17	Gerer, Kerstin	Erlangen, D	Characterization of NF-κB-optimized dendritic cells expressing the truncated large T antigen Merkel cell polyomavirus for therapeutic vaccination against Merkel cell carcinoma

**We thank our sponsors:**

Astra Zeneca GmbH (1.500 €), Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000 €), CureVac, CDDF (Cancer Drug Development Forum) (2.500 €), City of Halle, CureVac (2.000 €), Deutsche Forschungsgemeinschaft (DFG), Deutsche Gesellschaft für Immunologie (DGfI), Epiontis, Essen BioScience Ltd, Life Science Solutions PerkinElmer, Lipocalyx GmbH, Merck Serono GmbH (750 €), Miltenyi Biotec GmbH, nanoString Technologies, Novartis Pharma GmbH (750 €), Pfizer Pharma GmbH (1.000 €), Qiagen GmbH, Sarstedt, Sciomics GmbH, SERVA GmbH, SITC